NASDAQ:IMMY - Imprimis Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous Close$5.45
Today's Range$5.31 - $5.66
52-Week Range$1.45 - $6.50
Volume146,726 shs
Average Volume482,230 shs
Market Capitalization$121.29 million
P/E Ratio-9.08
Dividend YieldN/A
Imprimis Pharmaceuticals, Inc., an ophthalmology-focused pharmaceutical company, engages in the development, production, and sale of medications to physicians and patients in the United States. It offers ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications. The company also develops and commercializes therapeutics for the ocular surface diseases. In addition, it provides patent-pending preservative-free topical eye drop drug candidates, including SURF-100, an immunosuppressive drug that inhibits t-cell proliferation and replication in the dry eye disease (DED); SURF-200 for the patients with episodic DED; and SURF-300, a combination of a low-dose of doxycycline and a proprietary powderized triglyceride Omega-3 for the refractory DED patients with chronic DED symptoms. The company was formerly known as Transdel Pharmaceuticals, Inc. and changed its name to Imprimis Pharmaceuticals, Inc. in February 2012. Imprimis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in San Diego, California.

Receive IMMY News and Ratings via Email

Sign-up to receive the latest news and ratings for IMMY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:IMMY



Sales & Book Value

Annual Sales$26.77 million
Book Value$0.13 per share


Net Income$-11,980,000.00


Market Cap$121.29 million
Next Earnings DateN/A

Imprimis Pharmaceuticals (NASDAQ:IMMY) Frequently Asked Questions

What is Imprimis Pharmaceuticals' stock symbol?

Imprimis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IMMY."

How were Imprimis Pharmaceuticals' earnings last quarter?

Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) issued its quarterly earnings data on Monday, August, 6th. The specialty pharmaceutical company reported $0.12 earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.24. The specialty pharmaceutical company had revenue of $10.38 million for the quarter. Imprimis Pharmaceuticals had a negative return on equity of 231.16% and a negative net margin of 16.81%. View Imprimis Pharmaceuticals' Earnings History.

What price target have analysts set for IMMY?

2 Wall Street analysts have issued 1 year price targets for Imprimis Pharmaceuticals' stock. Their predictions range from $10.00 to $11.50. On average, they expect Imprimis Pharmaceuticals' stock price to reach $10.75 in the next year. View Analyst Price Targets for Imprimis Pharmaceuticals.

What is the consensus analysts' recommendation for Imprimis Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Imprimis Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Imprimis Pharmaceuticals.

Has Imprimis Pharmaceuticals been receiving favorable news coverage?

News headlines about IMMY stock have trended somewhat positive this week, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Imprimis Pharmaceuticals earned a media sentiment score of 0.6 on InfoTrie's scale. They also assigned news articles about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near term.

Who are some of Imprimis Pharmaceuticals' key competitors?

What other stocks do shareholders of Imprimis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Imprimis Pharmaceuticals investors own include Synergy Pharmaceuticals (SGYP), Heat Biologics (HTBX), Exelixis (EXEL), Progenics Pharmaceuticals (PGNX), Teva Pharmaceutical Industries (TEVA), Vereit (VER), Gilead Sciences (GILD), NVIDIA (NVDA), Karyopharm Therapeutics (KPTI) and Fate Therapeutics (FATE).

Who are Imprimis Pharmaceuticals' key executives?

Imprimis Pharmaceuticals' management team includes the folowing people:
  • Mr. Mark L. Baum, Founder, CEO & Director (Age 45)
  • Mr. Andrew R. Boll CFA, CMA, CFO & Corp. Sec. (Age 36)
  • Mr. John P. Saharek, Chief Commercial Officer (Age 58)
  • Mr. David Moufarrège, VP of Technology
  • Mr. Pramod Sharma Ph.D., VP of Quality

Who are Imprimis Pharmaceuticals' major shareholders?

Imprimis Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Opaleye Management Inc. (7.40%), Acadian Asset Management LLC (0.66%), Two Sigma Investments LP (0.50%), BlackRock Inc. (0.46%), Barclays PLC (0.24%) and Northern Trust Corp (0.19%). View Institutional Ownership Trends for Imprimis Pharmaceuticals.

Which institutional investors are selling Imprimis Pharmaceuticals stock?

IMMY stock was sold by a variety of institutional investors in the last quarter, including Granite Investment Partners LLC and Northern Trust Corp. View Insider Buying and Selling for Imprimis Pharmaceuticals.

Which institutional investors are buying Imprimis Pharmaceuticals stock?

IMMY stock was acquired by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Two Sigma Investments LP, Opaleye Management Inc., Barclays PLC, BlackRock Inc., SVA Plumb Wealth Management LLC and GSA Capital Partners LLP. View Insider Buying and Selling for Imprimis Pharmaceuticals.

How do I buy shares of Imprimis Pharmaceuticals?

Shares of IMMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How big of a company is Imprimis Pharmaceuticals?

Imprimis Pharmaceuticals has a market capitalization of $0.00 and generates $26.77 million in revenue each year. The specialty pharmaceutical company earns $-11,980,000.00 in net income (profit) each year or ($0.60) on an earnings per share basis.

What is Imprimis Pharmaceuticals' official website?

The official website for Imprimis Pharmaceuticals is

How can I contact Imprimis Pharmaceuticals?

Imprimis Pharmaceuticals' mailing address is 12264 El Camino Real Suite 350, San Diego CA, 92130. The specialty pharmaceutical company can be reached via phone at 858-704-4040 or via email at [email protected]

MarketBeat Community Rating for Imprimis Pharmaceuticals (NASDAQ IMMY)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  172 (Vote Outperform)
Underperform Votes:  165 (Vote Underperform)
Total Votes:  337
MarketBeat's community ratings are surveys of what our community members think about Imprimis Pharmaceuticals and other stocks. Vote "Outperform" if you believe IMMY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMMY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/22/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel